Previous close | 7.44 |
Open | 7.46 |
Bid | 7.37 x 100 |
Ask | 7.44 x 100 |
Day's range | 7.36 - 7.52 |
52-week range | 6.08 - 11.91 |
Volume | |
Avg. volume | 1,854,286 |
Market cap | 604.195M |
Beta (5Y monthly) | 2.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest full-year results and things are looking bullish...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52. EDIT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Editas […]